NCI-H3122 cell

SKU:BHC11101021
Bulk Pricing
Overview
Click light‑blue chips for details

NCI-H3122 cell is a cell line derived from Caucasian (Male). It is commonly used as an in vitro model for 1 research. Growth characteristics: Adherent. Supplied as cryopreserved cells with accompanying batch CoA and quality-control documentation.

Species Human
Disease model Adenocarcinoma
Growth Properties Adherent
Tissue Lung
Available Options

This cell line is available in the U.S. For non-profit users, please sign and submit the Non-Profit Supply Agreement to orders@biohippo.com before placing an order. For commercial users, please complete the CLEAR Form before ordering, as additional usage fees may apply based on the intended use. For further details, please contact orders@biohippo.com. Products ship after the required agreement is completed; typical delivery is 2–3 business days. Products are shipped frozen on dry ice in cryotubes. Each cryotube typically contains 3 × 10^6 cells for adherent lines or 5 × 10^6 cells for suspension lines (refer to the batch CoA for details).

Options selector
Catalog no. Size
300484 1 cryovial
Field Specification
Species Human
The NCI-H3122 cell line is derived from non-small-cell lung cancer (NSCLC) and is characterized by the presence of the EML4-ALK fusion gene, which results from a chromosomal translocation between echinoderm microtubule-associated protein-like 4 (EML4) and anaplastic lymphoma kinase (ALK). This fusion drives oncogenic signaling and makes NCI-H3122 cells highly dependent on ALK signaling for survival, known as "ALK-addicted." NCI-H3122 has become a key model for studying targeted therapies, particularly for ALK inhibitors like crizotinib. Studies have shown that NCI-H3122 cells are sensitive to crizotinib, which inhibits ALK phosphorylation and its downstream targets such as the AKT and ERK pathways. However, resistance to crizotinib often develops, typically due to alternative signaling pathways like the activation of the epidermal growth factor receptor (EGFR). This resistance mechanism has been confirmed in NCI-H3122 resistant variants, where increased EGFR phosphorylation was observed, and dual inhibition of ALK and EGFR using crizotinib and EGFR inhibitors such as afatinib or erlotinib was shown to overcome the resistance. NCI-H3122 is frequently used to explore combination therapies aimed at preventing or reversing drug resistance. For instance, targeting both ALK and EGFR pathways has been a successful strategy in preclinical models, and this dual inhibition has been suggested as a potential therapeutic approach for ALK-positive, crizotinib-resistant NSCLC patients.

SKU:BHC11101021

  • cultureMedium: RPMI 1640, w: 2.0 mM stable Glutamine, w: 2.0 g/L NaHCO3 (Cytion article number 820700a)
  • supplements: Supplement the medium with 10% FBS
  • dissociationReagent: Accutase
  • subculturing: Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium.
  • freezeMedium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.

Get a Quote

Please use this form for bulk quantity requests or customized products.

Contact Information

Product Information

Supplier Ads Slides show

Add dynamic ads with slider